CoChat

Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Clinical application of lentiviral vector (LV)‐based hematopoietic stem and progenitor cells (HSPC) gene therapy is rapidly becoming a reality. Nevertheless, LV‐mediated signaling and its potential functional consequences on HSPC biology remain poorly understood. We unravel here a remarkably limited impact of LV on the HSPC transcriptional landscape. LV escaped innate immune sensing that instead led to robust IFN responses upon transduction with a gamma‐retroviral vector. However, reverse‐transcribed LV DNA did trigger p53 signaling, activated also by non‐integrating Adeno‐associated vector, ultimately leading to lower cell recovery ex vivo and engraftment in vivo . These effects were more pronounced in the short‐term repopulating cells while long‐term HSC frequencies remained unaffected. Blocking LV‐induced signaling partially rescued both apoptosis and engraftment, highlighting a novel strategy to further dampen the impact of ex vivo gene transfer on HSPC. Overall, our results shed light on viral vector sensing in HSPC and provide critical insight for the development of more stealth gene therapy strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201707922

Cites

Statistics

Figures

Figure 1 LV transduction induces p53 signaling in human HSPC AScheme of the RNA‐Seq experiment performed on human cord blood (CB)‐derived CD34+ cells exposed to laboratory‐grade (Lab LV) or purified (purified LV) LV at a multiplicity of infection (MOI) of 100 or p24 equivalent of non‐transducing Env‐less (Bald LV), heat‐inactivated purified LV, or Poly(I:C).BPathway enrichment analysis of the differentially expressed genes over time (P ≤ 0.05) for Bald LV vs. Lab LV and inactivated purified LV vs. the purified LV.CHeatmap showing the profile over time of the most significantly (P ≤ 0.01) differentially expressed genes for Lab LV vs. Bald LV.DGenes differentially expressed for Lab LV vs. Bald LV are boxed in red in the KEGG p53 signaling pathway.EGene expression levels of p53‐induced genes in CB‐CD34+ cells 48 h after LV or Env‐less (Bald) LV exposure at MOI 100 or p24 equivalent (mean ± SEM, n = 8 for p48, PUMA and PHLDA3, n = 21 for p21, Wilcoxon signed‐rank test, **P = 0.0078 for p48 PUMA and PHLDA3, ****P < 0.0001 for p21.FCB‐CD34+ were sorted for the fractions enriched in stem cells (CD133+CD38−) and the more committed progenitors (CD133+CD38int and CD133+CD38hi).G, Hp21 mRNA levels were measured in the sorted fractions and bulk CB/BM‐CD34+ 48h after transduction at MOI 100 or p24 equivalent of controls (mean ± SEM, n = 5 for 133+38−, n = 8 for 133+38int and 133+38hi, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, G), (mean ± SEM, in CB n = 17 for Bald and LV, n = 11 for LV and n = 9 for Empty LV, in BM n = 8 for Bald and LV, n = 5 for IDLV and Empty LV, Dunn's adjusted Kruskal–Wallis test, **P ≤ 0.01, ***P ≤ 0.001, H).Ip21 mRNA levels measured in CB‐CD34+ transduced in the presence of the integrase inhibitor Raltegravir (Ral) or reverse‐transcriptase inhibitor Lamivudine (3TC) (mean ± SEM, n = 6 for Mock, n = 7 for DMSO and n = 8 for Raltegravir, n = 7 for 3TC, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).JWestern blot (left panel) and quantifications (right panel) were performed on whole mPB‐CD34+ cells extracts at 24 h post‐transduction (mean ± SEM, n = 4 for p53Ser15, n = 6 for p53, n = 5 for p21). The quantification was on WB performed from both mPB‐CD34+ and CB‐CD34+. One representative of four Western blot gels is shown.Kp21 protein up‐regulation evaluated by FACS 48 h after transduction (mean ± SEM, n = 7 for Mock, n = 11 for Bald, n = 4 for IDLV and n = 9 for LV, Dunn's adjusted Kruskal–Wallis test, **P ≤ 0.01, ***P ≤ 0.001).L–Np21 and ISG levels were measured in CB‐CD34+ exposed to LV, LV lacking the central polypurine tract (ΔcPPT) or γ‐RV at MOI 100 or p24 equivalent of Bald control vector, or MOI 10,000 of Adeno‐associated vector (AAV6) (mean ± SEM, n = 20 for Bald, n = 18 for LV, n = 16 for RV, and n = 14 for AAV6, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, L), (mean ± SEM, n = 14, Dunn's adjusted Friedman test, *P ≤ 0.05, ***P ≤ 0.001, Wilcoxon signed rank test, +++ P = 0.0004, M), (mean ± SEM, for IRF7 and OAS1 n = 18 for Bald and LV, n = 12 for ΔcPPT and RV and n = 8 for AAV6, n = 16 for RV and n = 14 for AAV6, for ISG15 n = 19 for Bald, LV and ΔcPPT, n = 8 for RV and n = 2 for AAV6, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, N). Source data are available online for this figure.
Figure 1 LV transduction induces p53 signaling in human HSPC AScheme of the RNA‐Seq experiment performed on human cord blood (CB)‐derived CD34+ cells exposed to laboratory‐grade (Lab LV) or purified (purified LV) LV at a multiplicity of infection (MOI) of 100 or p24 equivalent of non‐transducing Env‐less (Bald LV), heat‐inactivated purified LV, or Poly(I:C).BPathway enrichment analysis of the differentially expressed genes over time (P ≤ 0.05) for Bald LV vs. Lab LV and inactivated purified LV vs. the purified LV.CHeatmap showing the profile over time of the most significantly (P ≤ 0.01) differentially expressed genes for Lab LV vs. Bald LV.DGenes differentially expressed for Lab LV vs. Bald LV are boxed in red in the KEGG p53 signaling pathway.EGene expression levels of p53‐induced genes in CB‐CD34+ cells 48 h after LV or Env‐less (Bald) LV exposure at MOI 100 or p24 equivalent (mean ± SEM, n = 8 for p48, PUMA and PHLDA3, n = 21 for p21, Wilcoxon signed‐rank test, **P = 0.0078 for p48 PUMA and PHLDA3, ****P < 0.0001 for p21.FCB‐CD34+ were sorted for the fractions enriched in stem cells (CD133+CD38−) and the more committed progenitors (CD133+CD38int and CD133+CD38hi).G, Hp21 mRNA levels were measured in the sorted fractions and bulk CB/BM‐CD34+ 48h after transduction at MOI 100 or p24 equivalent of controls (mean ± SEM, n = 5 for 133+38−, n = 8 for 133+38int and 133+38hi, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, G), (mean ± SEM, in CB n = 17 for Bald and LV, n = 11 for LV and n = 9 for Empty LV, in BM n = 8 for Bald and LV, n = 5 for IDLV and Empty LV, Dunn's adjusted Kruskal–Wallis test, **P ≤ 0.01, ***P ≤ 0.001, H).Ip21 mRNA levels measured in CB‐CD34+ transduced in the presence of the integrase inhibitor Raltegravir (Ral) or reverse‐transcriptase inhibitor Lamivudine (3TC) (mean ± SEM, n = 6 for Mock, n = 7 for DMSO and n = 8 for Raltegravir, n = 7 for 3TC, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).JWestern blot (left panel) and quantifications (right panel) were performed on whole mPB‐CD34+ cells extracts at 24 h post‐transduction (mean ± SEM, n = 4 for p53Ser15, n = 6 for p53, n = 5 for p21). The quantification was on WB performed from both mPB‐CD34+ and CB‐CD34+. One representative of four Western blot gels is shown.Kp21 protein up‐regulation evaluated by FACS 48 h after transduction (mean ± SEM, n = 7 for Mock, n = 11 for Bald, n = 4 for IDLV and n = 9 for LV, Dunn's adjusted Kruskal–Wallis test, **P ≤ 0.01, ***P ≤ 0.001).L–Np21 and ISG levels were measured in CB‐CD34+ exposed to LV, LV lacking the central polypurine tract (ΔcPPT) or γ‐RV at MOI 100 or p24 equivalent of Bald control vector, or MOI 10,000 of Adeno‐associated vector (AAV6) (mean ± SEM, n = 20 for Bald, n = 18 for LV, n = 16 for RV, and n = 14 for AAV6, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, L), (mean ± SEM, n = 14, Dunn's adjusted Friedman test, *P ≤ 0.05, ***P ≤ 0.001, Wilcoxon signed rank test, +++ P = 0.0004, M), (mean ± SEM, for IRF7 and OAS1 n = 18 for Bald and LV, n = 12 for ΔcPPT and RV and n = 8 for AAV6, n = 16 for RV and n = 14 for AAV6, for ISG15 n = 19 for Bald, LV and ΔcPPT, n = 8 for RV and n = 2 for AAV6, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, N). Source data are available online for this figure.CC BY · PubMed Central
Figure EV1 Characterization of the transcriptional responses in HSPC APrincipal component analysis (PCA) plot. The samples from the RNA‐seq experiment are shown in the 3D plane spanned by their first three principal components. The first three principal components accounted for more than the 69% of explained variance among the data set.BBar chart of the pathway enrichment analysis performed with WikiPathways database on the significant (P ≤ 0.05) differentially expressed genes over time in the untreated condition or between the Poly(I:C) and Mock conditions. The length of the bar represents the significance (P‐value Ranking) of that specific pathway.Cp21 mRNA levels were measured after 48 h from the transduction of CB‐CD34+ with an MOI of 100 PGK‐GFP SIN LV (LV), MOI of 100 clinical‐grade LV (clinical LV), or to p24 equivalent of Env‐less (Bald) or inactivated clinical LV as controls (inactivated clinical LV) (mean ± SEM, n = 3).Dp21 mRNA levels 48 h post‐transduction and vector copy numbers (VCN) 14 days after transduction were measured in CB‐CD34+ exposed to increasing MOI of PGK‐GFP SIN LV (LV).Ep21 mRNA levels in CB‐CD34+ cells 5 days after transduction with an MOI 100 of LV, IDLV, or p24 equivalent of Bald or Empty LV as controls. Results are shown respect to Bald for each cell type set to value 1 (Red threshold) (mean ± SEM, n = 6).Fp21 mRNA levels 48 days post‐transduction in different human and murine cell lines or primary cells exposed to PGK‐GFP SIN LV or p24 equivalent of Bald as control. p21 mRNA was measured 48 h after the transduction and normalized to HPRT1 for human cells or Hprt for Murine cells. Results are shown respect to Bald for each cell type set to value 1 (Red threshold) (mean ± SEM, n = 17 for hu‐CD34+, n = 8 for mu‐HSPC, n = 3 for CD4+ T cells and HCT116, n = 4 for HL60, n = 2 for K562 and Hela).GVCN per cell were performed 14 days after exposure of sorted CB‐CD34+ to PGK‐GFP SIN LV (LV), at MOI 100 or p24 equivalents of Env‐less (Bald) as indicated (mean ± SEM, n = 5 for 133+38−, n = 8 for 133+38int and 133+38hi).HCopy number per cell of total viral DNA 3 days after the transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), integrase‐defective LV (IDLV), p24 equivalent genome‐less (Empty LV), or Env‐less (Bald) (mean ± SEM, n = 4).I, JVector copy number results and WB for p53 and p21 of CB‐CD34+ transduced with an MOI of 100 of PGK‐GFP SIN LV (LV), or Env‐less (Bald) as control. Transductions were performed in the presence of the integrase inhibitor Raltegravir (Ral), or the reverse‐transcriptase inhibitor Lamivudine (3TC). Control cells were transduced in DMSO or kept untreated (Mock). VCN and WB were performed 14 days and 48 h after transduction, respectively (mean ± SEM, n = 4, I; n = 1, J).KRepresentative FACS plot of CB‐CD34+ cells 48 h after the transduction with PGK‐BFP LV, IDLV, or Bald as control and stained with anti‐p21 antibody.LImmunofluorescence of CB‐CD34+ cells stained for γH2AX (left panel), 12 hours after the transduction with the indicated vector or camptothecin (CPT) exposure, and for p21 (right panel) 48 h after the transduction with PGK‐mCHERRY LV, IDLV, a p21 overexpressing LV (p21 OE) or Bald as a control (representative image of n = 2).MPercentage of GFP positive CB‐CD34+ transduced with PGK‐GFP SIN LV at MOI 100 (LV), or exposed to p24 equivalent of Env‐less (Bald) vector as control, cells were also transduced with an MOI 100 of a PGK‐GFP SIN RV or to an MOI 10,000 of PGK‐GFP Adeno‐associated Vector (AAV6). GFP expression was assessed at FACS 5 days after transduction for the integrating vector, and 2 days post‐TD for the AAV6 (mean ± SEM, n = 9).NVector copy number results of CB‐CD34+ transduced with PGK‐GFP SIN LV or PGK‐GFP SIN RV (RV) at MOI 100 or exposed to p24 equivalent of Env‐less (Bald) vector as control. Copy per cell of total viral DNA was assessed 3 days after transduction, while VCN on the integrated vectors were performed 14 days after transduction (mean ± SEM, n = 9).O, P(O) Comparison of the nuclear import efficiency and (P) total viral DNA 3 days after transduction with LV or ΔcPPT. Nuclear import efficiency is reported as the percentage of 2LTR circles on the total reverse‐transcribed viral DNA. The same analysis was performed in 293T cells (upper panel) and in human CBCD34+ cells (MOI 100) (lower panel) (mean ± SEM, n = 4 for 293T, n = 12 for CD34+, Mann–Whitney test, *P = 0.0286, ***P < 0.0001, O), (mean ± SEM, n = 4 for 293T, n = 12 for CD34+, Mann–Whitney test, P).QInterferon‐stimulated gene (ISG) expression in human CB‐CD34+ transduced with an MOI of 100 of PGK‐GFP SIN RV (γ‐RV), or heat‐inactivated RV (Inact RV) as control. Transductions were performed in the presence of the integrase inhibitor Raltegravir (Ral), reverse‐transcriptase inhibitor azidothymidine (AZT), or a neutralizing antibody against the human IFNα receptor (α‐IFNAR). FACS analysis of GFP expression was performed 2 days after the transduction (upper panel). ISGs (IRF7, OAS1, ISG15) were measured 48 h post‐transduction. Expression levels were normalized to HPRT1 and shown respect to Bald set to value of 1 (lower panel) (mean ± SEM, n = 6 for Inact RV, RV, RV + Ral, RV + AZT, n = 2 for RV + αIFNAR).RISG15 and p21 mRNA levels in CB‐CD34+ cells exposed to 1,000 U/ml of human IFNα for 24 h and transduced for 48 h either with an MOI 100 of a PGK‐GFP LV or p24 equivalent of Bald as a control (mean ± SEM, n = 2).SISG (IFIT1, IRF7, OAS1, and ISG15) induction in murine HSPC transduced with an MOI of 100 of PGK‐GFP SIN LV (LV), PGKGFP SIN RV (RV), or a p24 equivalent of Env‐less (Bald) 48 h post‐transduction. Cells were also left untreated as control in the mock condition. Expression levels were normalized to HPRT1 and shown respect to controls set to value of 1 (mean ± SEM, n = 3 for Mock, n = 8 for bald and LV, n = 4 for RV). Source data are available online for this figure.
Figure EV1 Characterization of the transcriptional responses in HSPC APrincipal component analysis (PCA) plot. The samples from the RNA‐seq experiment are shown in the 3D plane spanned by their first three principal components. The first three principal components accounted for more than the 69% of explained variance among the data set.BBar chart of the pathway enrichment analysis performed with WikiPathways database on the significant (P ≤ 0.05) differentially expressed genes over time in the untreated condition or between the Poly(I:C) and Mock conditions. The length of the bar represents the significance (P‐value Ranking) of that specific pathway.Cp21 mRNA levels were measured after 48 h from the transduction of CB‐CD34+ with an MOI of 100 PGK‐GFP SIN LV (LV), MOI of 100 clinical‐grade LV (clinical LV), or to p24 equivalent of Env‐less (Bald) or inactivated clinical LV as controls (inactivated clinical LV) (mean ± SEM, n = 3).Dp21 mRNA levels 48 h post‐transduction and vector copy numbers (VCN) 14 days after transduction were measured in CB‐CD34+ exposed to increasing MOI of PGK‐GFP SIN LV (LV).Ep21 mRNA levels in CB‐CD34+ cells 5 days after transduction with an MOI 100 of LV, IDLV, or p24 equivalent of Bald or Empty LV as controls. Results are shown respect to Bald for each cell type set to value 1 (Red threshold) (mean ± SEM, n = 6).Fp21 mRNA levels 48 days post‐transduction in different human and murine cell lines or primary cells exposed to PGK‐GFP SIN LV or p24 equivalent of Bald as control. p21 mRNA was measured 48 h after the transduction and normalized to HPRT1 for human cells or Hprt for Murine cells. Results are shown respect to Bald for each cell type set to value 1 (Red threshold) (mean ± SEM, n = 17 for hu‐CD34+, n = 8 for mu‐HSPC, n = 3 for CD4+ T cells and HCT116, n = 4 for HL60, n = 2 for K562 and Hela).GVCN per cell were performed 14 days after exposure of sorted CB‐CD34+ to PGK‐GFP SIN LV (LV), at MOI 100 or p24 equivalents of Env‐less (Bald) as indicated (mean ± SEM, n = 5 for 133+38−, n = 8 for 133+38int and 133+38hi).HCopy number per cell of total viral DNA 3 days after the transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), integrase‐defective LV (IDLV), p24 equivalent genome‐less (Empty LV), or Env‐less (Bald) (mean ± SEM, n = 4).I, JVector copy number results and WB for p53 and p21 of CB‐CD34+ transduced with an MOI of 100 of PGK‐GFP SIN LV (LV), or Env‐less (Bald) as control. Transductions were performed in the presence of the integrase inhibitor Raltegravir (Ral), or the reverse‐transcriptase inhibitor Lamivudine (3TC). Control cells were transduced in DMSO or kept untreated (Mock). VCN and WB were performed 14 days and 48 h after transduction, respectively (mean ± SEM, n = 4, I; n = 1, J).KRepresentative FACS plot of CB‐CD34+ cells 48 h after the transduction with PGK‐BFP LV, IDLV, or Bald as control and stained with anti‐p21 antibody.LImmunofluorescence of CB‐CD34+ cells stained for γH2AX (left panel), 12 hours after the transduction with the indicated vector or camptothecin (CPT) exposure, and for p21 (right panel) 48 h after the transduction with PGK‐mCHERRY LV, IDLV, a p21 overexpressing LV (p21 OE) or Bald as a control (representative image of n = 2).MPercentage of GFP positive CB‐CD34+ transduced with PGK‐GFP SIN LV at MOI 100 (LV), or exposed to p24 equivalent of Env‐less (Bald) vector as control, cells were also transduced with an MOI 100 of a PGK‐GFP SIN RV or to an MOI 10,000 of PGK‐GFP Adeno‐associated Vector (AAV6). GFP expression was assessed at FACS 5 days after transduction for the integrating vector, and 2 days post‐TD for the AAV6 (mean ± SEM, n = 9).NVector copy number results of CB‐CD34+ transduced with PGK‐GFP SIN LV or PGK‐GFP SIN RV (RV) at MOI 100 or exposed to p24 equivalent of Env‐less (Bald) vector as control. Copy per cell of total viral DNA was assessed 3 days after transduction, while VCN on the integrated vectors were performed 14 days after transduction (mean ± SEM, n = 9).O, P(O) Comparison of the nuclear import efficiency and (P) total viral DNA 3 days after transduction with LV or ΔcPPT. Nuclear import efficiency is reported as the percentage of 2LTR circles on the total reverse‐transcribed viral DNA. The same analysis was performed in 293T cells (upper panel) and in human CBCD34+ cells (MOI 100) (lower panel) (mean ± SEM, n = 4 for 293T, n = 12 for CD34+, Mann–Whitney test, *P = 0.0286, ***P < 0.0001, O), (mean ± SEM, n = 4 for 293T, n = 12 for CD34+, Mann–Whitney test, P).QInterferon‐stimulated gene (ISG) expression in human CB‐CD34+ transduced with an MOI of 100 of PGK‐GFP SIN RV (γ‐RV), or heat‐inactivated RV (Inact RV) as control. Transductions were performed in the presence of the integrase inhibitor Raltegravir (Ral), reverse‐transcriptase inhibitor azidothymidine (AZT), or a neutralizing antibody against the human IFNα receptor (α‐IFNAR). FACS analysis of GFP expression was performed 2 days after the transduction (upper panel). ISGs (IRF7, OAS1, ISG15) were measured 48 h post‐transduction. Expression levels were normalized to HPRT1 and shown respect to Bald set to value of 1 (lower panel) (mean ± SEM, n = 6 for Inact RV, RV, RV + Ral, RV + AZT, n = 2 for RV + αIFNAR).RISG15 and p21 mRNA levels in CB‐CD34+ cells exposed to 1,000 U/ml of human IFNα for 24 h and transduced for 48 h either with an MOI 100 of a PGK‐GFP LV or p24 equivalent of Bald as a control (mean ± SEM, n = 2).SISG (IFIT1, IRF7, OAS1, and ISG15) induction in murine HSPC transduced with an MOI of 100 of PGK‐GFP SIN LV (LV), PGKGFP SIN RV (RV), or a p24 equivalent of Env‐less (Bald) 48 h post‐transduction. Cells were also left untreated as control in the mock condition. Expression levels were normalized to HPRT1 and shown respect to controls set to value of 1 (mean ± SEM, n = 3 for Mock, n = 8 for bald and LV, n = 4 for RV). Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 In vitro impact of LV Ap21 expression levels 48 h after the transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), p21 overexpressing LV (p21 OE) or p24 equivalent of Bald (mean ± SEM, n = 8).BRepresentative gating strategy to analyze the CD34+ cells treated as in Fig 2A. The upper panel shows the percentage of CD34+, CD133+, and CD90+ cells at the moment of transduction, the lower panel reports the same markers 2 days after the transduction. In the right panels, the bar graphs show the MFI of the cell proliferation dye at the moment of transduction or 4 and 6 days after the transduction within each subpopulation (mean ± SEM, n = 8, Wilcoxon matched pairs test, *P = 0.0313 for t4, *P = 0.0156 and **P = 0.0078 for t6).C, D(C) Representative histograms and (D) bar graphs of cells treated as in Fig 2A at 2 days after transduction. The analyses were performed to assess the percentage of CB‐CD34+ cells that are contained within each gate (C1, C2, C3) for LV, p21, and Bald conditions. The cells within the C1 gate have proliferated less, while the one in the C3 have proliferated more (mean ± SEM, n = 8, Wilcoxon signed‐rank test, *P = 0.0142, **P = 0.0078, left panel) (mean ± SEM, n = 6, right panel).EAnnexin V staining for apoptotic cells was performed 2 days after transduction of human CB‐CD34+ exposed to increasing MOI of PGK‐GFP SIN LV (LV) (mean ± SEM, n = 6).FAfter the sorting and transduction as indicated in Fig 1F, CB‐CD34+ cells were plated in semisolid, cytokine‐containing CFC medium. Colonies were scored after 14 days (mean ± SEM, n = 4, Wilcoxon signed‐rank test, *P = 0.0416, **P = 0.0078 in 133+38−, **P = 0.0011 in 133+38int, ***P = 0.004).G, HAnnexin staining for apoptotic cells was performed 2 days after transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), MOI of 100 clinical‐grade LV (clinical LV), MOI 10,000 of AAV6 and MOI 100 of PGK‐GFP SINRV (RV) or to p24 equivalent of Env‐less (Bald) or inactivated clinical LV as controls (Inactivated clinical LV) (mean ± SEM, n = 3, G), (mean ± SEM, n = 11 for Bald, LV and AAV6, n = 7 for RV, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05; **P ≤ 0.01, H).
Figure EV2 In vitro impact of LV Ap21 expression levels 48 h after the transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), p21 overexpressing LV (p21 OE) or p24 equivalent of Bald (mean ± SEM, n = 8).BRepresentative gating strategy to analyze the CD34+ cells treated as in Fig 2A. The upper panel shows the percentage of CD34+, CD133+, and CD90+ cells at the moment of transduction, the lower panel reports the same markers 2 days after the transduction. In the right panels, the bar graphs show the MFI of the cell proliferation dye at the moment of transduction or 4 and 6 days after the transduction within each subpopulation (mean ± SEM, n = 8, Wilcoxon matched pairs test, *P = 0.0313 for t4, *P = 0.0156 and **P = 0.0078 for t6).C, D(C) Representative histograms and (D) bar graphs of cells treated as in Fig 2A at 2 days after transduction. The analyses were performed to assess the percentage of CB‐CD34+ cells that are contained within each gate (C1, C2, C3) for LV, p21, and Bald conditions. The cells within the C1 gate have proliferated less, while the one in the C3 have proliferated more (mean ± SEM, n = 8, Wilcoxon signed‐rank test, *P = 0.0142, **P = 0.0078, left panel) (mean ± SEM, n = 6, right panel).EAnnexin V staining for apoptotic cells was performed 2 days after transduction of human CB‐CD34+ exposed to increasing MOI of PGK‐GFP SIN LV (LV) (mean ± SEM, n = 6).FAfter the sorting and transduction as indicated in Fig 1F, CB‐CD34+ cells were plated in semisolid, cytokine‐containing CFC medium. Colonies were scored after 14 days (mean ± SEM, n = 4, Wilcoxon signed‐rank test, *P = 0.0416, **P = 0.0078 in 133+38−, **P = 0.0011 in 133+38int, ***P = 0.004).G, HAnnexin staining for apoptotic cells was performed 2 days after transduction of human CB‐CD34+ exposed to an MOI of 100 PGK‐GFP SIN LV (LV), MOI of 100 clinical‐grade LV (clinical LV), MOI 10,000 of AAV6 and MOI 100 of PGK‐GFP SINRV (RV) or to p24 equivalent of Env‐less (Bald) or inactivated clinical LV as controls (Inactivated clinical LV) (mean ± SEM, n = 3, G), (mean ± SEM, n = 11 for Bald, LV and AAV6, n = 7 for RV, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05; **P ≤ 0.01, H).CC BY · PubMed Central
Figure 2 Functional consequences of LV‐mediated signaling in human HSPC in vitro ACell proliferation of CB‐CD34+ cells transduced with MOI 100 of LV, p21 overexpressing LV (p21) or p24 equivalent of Bald (mean ± SEM, n = 8, Wilcoxon signed‐rank test, *P = 0.0156, **P = 0.0078 in CD34+133−, CD34+133+, CD34+133+90+, *P = 0.0234, **P = 0.0078 in Bulk CD34+).BCell cycle analysis 2 days after the transduction (mean ± SEM, n = 6).C–EApoptosis was evaluated 2 days after exposure of total or sorted CB‐CD34+ to LV, integrase‐defective LV (IDLV) or Env‐less (Bald) at MOI 100 or p24 equivalents (mean ± SEM, n = 12, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, C) (mean ± SEM, n = 4 for 133+38−, n = 7 for 133+38int and 133+38hi, Wilcoxon signed‐rank test, *P = 0.0223 in late apoptotic, *P = 0.0156 in live and early apoptotic, E). (D) CB‐CD34+ cells were counted 2, 4, and 6 days after the transduction (mean ± SEM, n = 4, Wilcoxon signed‐rank test, **P = 0.0039).FColony‐forming unit (CFU) output after 2 weeks of differentiation (mean ± SEM, n = 10, Wilcoxon signed‐rank test, *P = 0.0170).GImpact of integrase (Ral) or reverse‐transcriptase (3TC) inhibition on apoptosis (mean ± SEM, n = 8 for Mock and Ral, n = 7 for DMSO and 3TC, Wilcoxon signed‐rank test, *P = 0.0156, **P = 0.0078).
Figure 2 Functional consequences of LV‐mediated signaling in human HSPC in vitro ACell proliferation of CB‐CD34+ cells transduced with MOI 100 of LV, p21 overexpressing LV (p21) or p24 equivalent of Bald (mean ± SEM, n = 8, Wilcoxon signed‐rank test, *P = 0.0156, **P = 0.0078 in CD34+133−, CD34+133+, CD34+133+90+, *P = 0.0234, **P = 0.0078 in Bulk CD34+).BCell cycle analysis 2 days after the transduction (mean ± SEM, n = 6).C–EApoptosis was evaluated 2 days after exposure of total or sorted CB‐CD34+ to LV, integrase‐defective LV (IDLV) or Env‐less (Bald) at MOI 100 or p24 equivalents (mean ± SEM, n = 12, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, C) (mean ± SEM, n = 4 for 133+38−, n = 7 for 133+38int and 133+38hi, Wilcoxon signed‐rank test, *P = 0.0223 in late apoptotic, *P = 0.0156 in live and early apoptotic, E). (D) CB‐CD34+ cells were counted 2, 4, and 6 days after the transduction (mean ± SEM, n = 4, Wilcoxon signed‐rank test, **P = 0.0039).FColony‐forming unit (CFU) output after 2 weeks of differentiation (mean ± SEM, n = 10, Wilcoxon signed‐rank test, *P = 0.0170).GImpact of integrase (Ral) or reverse‐transcriptase (3TC) inhibition on apoptosis (mean ± SEM, n = 8 for Mock and Ral, n = 7 for DMSO and 3TC, Wilcoxon signed‐rank test, *P = 0.0156, **P = 0.0078).CC BY · PubMed Central
Figure 3 In vivo impact of LV‐mediated signaling ASchematic representation of the experimental design.BPercentages of total human CD45+ cells were monitored in the peripheral blood over time and in the bone marrow at the end of the experiment (each dot representing a single mouse, n = 10 for Empty LV, n = 9 for Mix and LV, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).CSchematic representation of the experimental design and percentages of total human CD45+ cells monitored in the peripheral blood over time and in the bone marrow at the end of the experiments (each dot representing a single mouse, n = 5 for inact LV, n = 4 for LV, Mann–Whitney test, *P = 0.0491).DPercentages and absolute numbers of human CD34+ cells retrieved from the bone marrow of NSG mice 16 h post‐transplantation (each dot representing a single mouse, n = 2 for not transplanted (no TP ctrl) mice, n = 4 for Bald and LV).E, FRepresentative FACS plots and frequencies of CD34+, CD34+38+, and CD34+CD38− within the human CD45+ cells and of CD45RA−90+ (HSC), CD45RA−90− (MPP), and CD45RA+90− (MLP) within the human CD34+38− cells retrieved from the bone marrow of primary recipients (mean ± SEM, lower panel, or each dot representing a single mouse, upper right panel, n = 10 for Empty LV, n = 9 for Mix and LV, E), (mean ± SEM, n = 7 for Empty LV and Mix, n = 6 for LV, F).G, HPercentages of CD45+ cells in the peripheral blood and frequency of CD34+ cells within the bone marrow of the secondary recipients are shown (each dot representing a single mouse, n = 10 for Empty LV, n = 9 for LV and n = 11 for Mix, G and H).ITable and plot of the calculated HSC frequency obtained by LDA for untransduced (Bald) and MOI 100 transduced (LV) CB‐CD34+ cells (n = 2 in Bald and n = 4 in LV for 3,000 cells, n = 3 for 10,000 and 30,000 cells, n = 4 for 90,000 cells, n = 2 for not transplanted controls). Each dot represents a single mouse. HSC = hematopoietic stem cells, MPP = multipotent progenitors, MLP = multilymphoid progenitors.
Figure 3 In vivo impact of LV‐mediated signaling ASchematic representation of the experimental design.BPercentages of total human CD45+ cells were monitored in the peripheral blood over time and in the bone marrow at the end of the experiment (each dot representing a single mouse, n = 10 for Empty LV, n = 9 for Mix and LV, Dunn's adjusted Kruskal–Wallis test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).CSchematic representation of the experimental design and percentages of total human CD45+ cells monitored in the peripheral blood over time and in the bone marrow at the end of the experiments (each dot representing a single mouse, n = 5 for inact LV, n = 4 for LV, Mann–Whitney test, *P = 0.0491).DPercentages and absolute numbers of human CD34+ cells retrieved from the bone marrow of NSG mice 16 h post‐transplantation (each dot representing a single mouse, n = 2 for not transplanted (no TP ctrl) mice, n = 4 for Bald and LV).E, FRepresentative FACS plots and frequencies of CD34+, CD34+38+, and CD34+CD38− within the human CD45+ cells and of CD45RA−90+ (HSC), CD45RA−90− (MPP), and CD45RA+90− (MLP) within the human CD34+38− cells retrieved from the bone marrow of primary recipients (mean ± SEM, lower panel, or each dot representing a single mouse, upper right panel, n = 10 for Empty LV, n = 9 for Mix and LV, E), (mean ± SEM, n = 7 for Empty LV and Mix, n = 6 for LV, F).G, HPercentages of CD45+ cells in the peripheral blood and frequency of CD34+ cells within the bone marrow of the secondary recipients are shown (each dot representing a single mouse, n = 10 for Empty LV, n = 9 for LV and n = 11 for Mix, G and H).ITable and plot of the calculated HSC frequency obtained by LDA for untransduced (Bald) and MOI 100 transduced (LV) CB‐CD34+ cells (n = 2 in Bald and n = 4 in LV for 3,000 cells, n = 3 for 10,000 and 30,000 cells, n = 4 for 90,000 cells, n = 2 for not transplanted controls). Each dot represents a single mouse. HSC = hematopoietic stem cells, MPP = multipotent progenitors, MLP = multilymphoid progenitors.CC BY · PubMed Central
Figure EV3 Liquid culture, CFU, and in vivo transduction of in vivo experiments A–E(A) Transduction efficiency at 5 days, (B) VCN at 14 days after (C) p21 mRNA induction (D) CFU counts and (E) Annexin V staining at 48 h after transduction of the cells that were transplanted in NSG Mice (Fig 3) (mean ± SEM, n = 2, A–E).FVCN retrieved from the liquid culture of mPB‐CD34+ 14 days after transduction with the two‐hit clinical standard protocol as described in Fig 3C (n = 1).G–IPercentage of the GFP+, and (H) myeloid (CD13+), lymphoid (CD19+ B, CD3+ T) cells within the human CD45+ cells in the peripheral blood over time, spleen and BM at the end of the experiment of the primary or secondary mice (mean ± SEM, n = 9 for LV and Mix, n = 10 for Empty LV, G, H) (mean ± SEM, n = 9 for LV, n = 10 for Empty LV and n = 11 for Mix, I).JFrequencies of CD34+38+ and CD34+CD38− within the human CD34+ cells retrieved from the bone marrow of secondary recipients at the end of the experiment (mean ± SEM, n = 9 for LV, n = 10 for Empty LV and n = 11 for Mix).KPercentages of human CD45+ cells (left panel) detected in the bone marrow of NSG mice at 16 weeks after the transplant in the limiting dilution assay (LDA) experiment, and (right panel) the real number of CB‐CD34+ cells injected in the mice for the same experiment (each dot representing one mouse, n = 2 in Bald and n = 4 in LV for 3,000 cells, n = 3 for 10,000 and 30,000 cells, n = 4 for 90,000 cells, n = 2 for not transplanted controls, left panel) (each dot representing the number of cells injected in one mouse).LInterferon‐stimulated genes (left panel) mRNA levels in CB‐CD34+ 48 h after the transduction with an MOI 100 of PGK‐SIN RV vector in the presence of KU55933 ATM inhibitor, (right panel) cell proliferation assay in CB CD34+ 2 days after the transduction with MOI 100 of PGK LV in DMSO or KU55933 or MOI 100 of PGK RV or empty RV as control (mean ± SEM, n = 2).M, N(M) Myeloid (CD13+), lymphoid (CD19+ B, CD3+ T), and (N) GFP+ cells within the human CD45+ cells were monitored in the peripheral blood over time (mean ± SEM, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, M) (each dot representing one mouse, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, N). D = DMSO, K = KU55933.
Figure EV3 Liquid culture, CFU, and in vivo transduction of in vivo experiments A–E(A) Transduction efficiency at 5 days, (B) VCN at 14 days after (C) p21 mRNA induction (D) CFU counts and (E) Annexin V staining at 48 h after transduction of the cells that were transplanted in NSG Mice (Fig 3) (mean ± SEM, n = 2, A–E).FVCN retrieved from the liquid culture of mPB‐CD34+ 14 days after transduction with the two‐hit clinical standard protocol as described in Fig 3C (n = 1).G–IPercentage of the GFP+, and (H) myeloid (CD13+), lymphoid (CD19+ B, CD3+ T) cells within the human CD45+ cells in the peripheral blood over time, spleen and BM at the end of the experiment of the primary or secondary mice (mean ± SEM, n = 9 for LV and Mix, n = 10 for Empty LV, G, H) (mean ± SEM, n = 9 for LV, n = 10 for Empty LV and n = 11 for Mix, I).JFrequencies of CD34+38+ and CD34+CD38− within the human CD34+ cells retrieved from the bone marrow of secondary recipients at the end of the experiment (mean ± SEM, n = 9 for LV, n = 10 for Empty LV and n = 11 for Mix).KPercentages of human CD45+ cells (left panel) detected in the bone marrow of NSG mice at 16 weeks after the transplant in the limiting dilution assay (LDA) experiment, and (right panel) the real number of CB‐CD34+ cells injected in the mice for the same experiment (each dot representing one mouse, n = 2 in Bald and n = 4 in LV for 3,000 cells, n = 3 for 10,000 and 30,000 cells, n = 4 for 90,000 cells, n = 2 for not transplanted controls, left panel) (each dot representing the number of cells injected in one mouse).LInterferon‐stimulated genes (left panel) mRNA levels in CB‐CD34+ 48 h after the transduction with an MOI 100 of PGK‐SIN RV vector in the presence of KU55933 ATM inhibitor, (right panel) cell proliferation assay in CB CD34+ 2 days after the transduction with MOI 100 of PGK LV in DMSO or KU55933 or MOI 100 of PGK RV or empty RV as control (mean ± SEM, n = 2).M, N(M) Myeloid (CD13+), lymphoid (CD19+ B, CD3+ T), and (N) GFP+ cells within the human CD45+ cells were monitored in the peripheral blood over time (mean ± SEM, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, M) (each dot representing one mouse, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, N). D = DMSO, K = KU55933.CC BY · PubMed Central
Figure 4 Inhibition of LV signaling rescues HSPC apoptosis and engraftment Ap21 mRNA levels measured 24 h after the second hit of transduction and 6 hours after CPT treatment in CB‐CD34+ overexpressing a dominant negative form of p53 (GSE56) or GFP as control (mean ± SEM, n = 6 for Bald and LV 2nd hit, n = 2 for AAV6 2nd hit and n = 5 for CPT 2nd hit).BApoptosis was evaluated 48 h after the second hit of transduction with (Bald, LV, or AAV6 vectors) in CB‐CD34+ overexpressing GSE56 or GFP as control. (mean ± SEM, n = 2).Cp21 mRNA induction was measured 48 h post‐exposure in CB‐CD34+ cells transduced with LV or Bald control at MOI 100 or p24 equivalent in the presence of 10 μM KU55933 (mean ± SEM, n = 9, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, Wilcoxon signed‐rank test, ++ P = 0.0039).DWestern Blot (n = 1) (left panel) and representative plot of p21 FACS staining (right panel) were performed on whole mPB‐CD34+ and CB‐CD34+ 24 and 48 h after the transduction, respectively, in the presence of 10 μM KU55933.E, FApoptosis and transduction efficiency were measured 48 h and 5 days post‐exposure, respectively, in CB‐CD34+ cells transduced with LV or Bald control at MOI 100 or p24 equivalent in the presence of 10 μM KU55933 (mean ± SEM, n = 15, Wilcoxon signed‐rank test, **P = 0.0061, *P = 0.0105, E).G–IImpact of ATM inhibition on apoptosis, CFC assay, and p21 mRNA induction on mPB‐CD34+ cells after transduction with two hits at MOI 100 of clinical‐grade LV or p21 equivalent of inactivated clinical LV (inact LV) as a control (mean ± SEM, n = 3, G), (mean ± SEM, n = 3, Dunn's adjusted Friedman test, *P ≤ 0.05, H) (mean ± SEM, n = 2, I).J, KImpact of ATM inhibition on AAV6‐mediated induction of p21 mRNA and apoptosis (mean ± SEM, n = 6, Dunn's adjusted Friedman test, *P ≤ 0.05, Wilcoxon signed‐rank test, + P = 0.0313, J), (mean ± SEM, n = 6, Wilcoxon signed‐rank test, *P = 0.0313, K).L, M In vivo impact of ATM inhibition on total human CD45+ cells in the peripheral blood over time (mean ± SEM, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, Mann–Whitney test, *P = 0.0434, for Bald vs. LV, *P = 0.0411 for LV D vs. LV K at 7 weeks, **P = 0.0043, M). Source data are available online for this figure.
Figure 4 Inhibition of LV signaling rescues HSPC apoptosis and engraftment Ap21 mRNA levels measured 24 h after the second hit of transduction and 6 hours after CPT treatment in CB‐CD34+ overexpressing a dominant negative form of p53 (GSE56) or GFP as control (mean ± SEM, n = 6 for Bald and LV 2nd hit, n = 2 for AAV6 2nd hit and n = 5 for CPT 2nd hit).BApoptosis was evaluated 48 h after the second hit of transduction with (Bald, LV, or AAV6 vectors) in CB‐CD34+ overexpressing GSE56 or GFP as control. (mean ± SEM, n = 2).Cp21 mRNA induction was measured 48 h post‐exposure in CB‐CD34+ cells transduced with LV or Bald control at MOI 100 or p24 equivalent in the presence of 10 μM KU55933 (mean ± SEM, n = 9, Dunn's adjusted Kruskal–Wallis test, ***P ≤ 0.001, Wilcoxon signed‐rank test, ++ P = 0.0039).DWestern Blot (n = 1) (left panel) and representative plot of p21 FACS staining (right panel) were performed on whole mPB‐CD34+ and CB‐CD34+ 24 and 48 h after the transduction, respectively, in the presence of 10 μM KU55933.E, FApoptosis and transduction efficiency were measured 48 h and 5 days post‐exposure, respectively, in CB‐CD34+ cells transduced with LV or Bald control at MOI 100 or p24 equivalent in the presence of 10 μM KU55933 (mean ± SEM, n = 15, Wilcoxon signed‐rank test, **P = 0.0061, *P = 0.0105, E).G–IImpact of ATM inhibition on apoptosis, CFC assay, and p21 mRNA induction on mPB‐CD34+ cells after transduction with two hits at MOI 100 of clinical‐grade LV or p21 equivalent of inactivated clinical LV (inact LV) as a control (mean ± SEM, n = 3, G), (mean ± SEM, n = 3, Dunn's adjusted Friedman test, *P ≤ 0.05, H) (mean ± SEM, n = 2, I).J, KImpact of ATM inhibition on AAV6‐mediated induction of p21 mRNA and apoptosis (mean ± SEM, n = 6, Dunn's adjusted Friedman test, *P ≤ 0.05, Wilcoxon signed‐rank test, + P = 0.0313, J), (mean ± SEM, n = 6, Wilcoxon signed‐rank test, *P = 0.0313, K).L, M In vivo impact of ATM inhibition on total human CD45+ cells in the peripheral blood over time (mean ± SEM, n = 8 for Bald DMSO, n = 10 for LV DMSO, n = 11 for Bald and LV KU55933, Mann–Whitney test, *P = 0.0434, for Bald vs. LV, *P = 0.0411 for LV D vs. LV K at 7 weeks, **P = 0.0043, M). Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 65 · Cited by 75

Metadata

Authors
Piras, F., Riba, M., Petrillo, C., Lazarevic, D., Cuccovillo, I., Bartolaccini, S., Stupka, E., Gentner, B., Cittaro, D., Naldini, L., & Kajaste‐Rudnitski, A.
Affiliations
  • Vita-Salute San Raffaele University (IT)
  • IRCCS Ospedale San Raffaele (IT)
  • The San Raffaele Telethon Institute for Gene Therapy (IT)
Corresponding author
Kajaste‐Rudnitski, Anna
Venue
EMBO Molecular Medicine
Published
2017-06-30
Volume
9
Issue
9
Pages
1198-1211
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2729942300
Cited by
75
References
65
Citations by year
2026: 5 · 2025: 9 · 2024: 8 · 2023: 14 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 7 · 2018: 5 · 2017: 1
FWCI
3.62
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Funders
  • Fondazione Telethon (TGT14D04, TELE16C3, TGT)
  • Ministero della Salute (GR‐2009‐1471693)
  • Fanconi Anemia Research Fund (FARF)
  • H2020 European Research Council (TARGETINGGENETHERAPY)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
lentiviral vectors, hematopoietic stem and progenitor cells, innate immune recognition, p53 pathway, interferon response, gene therapy, ex vivo gene transfer, engraftment, apoptosis, long-term hematopoietic stem cells, adeno-associated virus, gammaretroviral vectors, transcriptional landscape
MeSH terms
Animals, Genetic Vectors, Hematopoietic Stem Cells, Humans, Immunity, Innate, Genetic Therapy, Lentivirus, Tumor Suppressor Protein p53, Hematopoietic Stem Cell Transplantation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. https://app.cochat.ai/papers/10.15252/emmm.201707922
The paper
Piras, F., Riba, M., Petrillo, C., Lazarevic, D., Cuccovillo, I., Bartolaccini, S., Stupka, E., Gentner, B., Cittaro, D., Naldini, L., & Kajaste‐Rudnitski, A. (2017). Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201707922

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.